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Palladium(II) complexes with thiosemicarbazones
derived from pyrene as topoisomerase IB
inhibitors†
Carolina G. Oliveira, a,b,c Isolda Romero-Canelón, c,d Monize M. Silva,e
James P. C. Coverdale, e Pedro Ivo S. Maia,f Alzir A. Batista, e Silvia Castelli,g
Alessandro Desideri,*g Peter J. Sadler *c and Victor M. Deflon *a
New palladium complexes with thiosemicarbazonate ligands derived from pyrene exhibit potent antiproli-
ferative activity against A2780 and cisplatin-resistant A2780Cis human ovarian cancer cells, which is
dependent on substituent groups of the thiosemicarbazone ligands. Cellular accumulation and distri-
bution studies confirmed that palladium enters the cell nucleus. DNA and topoisomerase IB studies show
that one complex is a potent TopIB inhibitor, with selectivity for cancer versus normal cells.
Introduction
Thiosemicarbazones (TSCs) have been extensively studied due
to their ability to chelate several metal ions1 and to suppress
tumor growth by inhibiting ribonucleotide reductase (RR), a
key enzyme required for DNA synthesis.2,3 Another well-known
target for some TSCs derivatives is Topoisomerase (Top),
responsible for DNA topology regulation during cell division.4
Recently, it was shown that the cytotoxicity of Dp44mT
(di-2-pyridylketone-4,4-dimethyl-3-thiosemi-carbazone, Chart 1)
against breast cancer cells is caused by poisoning topoisome-
rase IIa.5 Dp44mT is structurally similar to triapine (Chart 1), a
compound which has undergone Phase 1 and 2 clinical
trials.6,7 Both topoisomerase I (Top I) and topoisomerase II
(Top II) have been established as effective molecular targets
for many antitumor drugs. Several transition metal complexes
have been shown to react with topoisomerase IB and act as
poisons and/or catalytic inhibitors, since tumor cells present
high levels of Top enzymes.8,9 Top IB is the cellular target of
camptothecin (CPT), a compound which generated the ana-
logues topotecan and irinotecan, currently in clinical use to
treat ovarian and colorectal cancers.10,11 Besides, the
functionalization of TSCs provides a strategy to improve their
efficiency and to incorporate specific properties. A pyrene
group present in a thiosemicarbazone compound might bring
new characteristics to the ligand, like fluorescence,12 that
would enable its use as a luminescent probe for tracking com-
plexes inside cells. Furthermore, the intercalating properties of
pyrene can be used to inhibit cellular DNA replication.13,14
Hence, thiosemicarbazone ligands containing a pyrene moiety
(Chart 1) might be promising to achieve metal complexes with
mechanisms of action different from cisplatin, making them
potentially active against platinum-resistant cell lines.
In addition to the potential use of thiosemicarbazones in
cancer therapy, their derivatives with metal complexes are of
considerable interest. New metal complexes might have
increased efficacy and the possibility of overcoming resistance,
which are the major limitations of the platinum anticancer
drugs used in chemotherapy.15,16 In this regard, palladium
Chart 1 Molecular structure of thiosemicarbazones Dp44mT, triapine
and the ligands studied here.
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complexes are natural analogues of platinum. However, palla-
dium complexes usually exhibit high lability towards ligand
exchange which limits their use.17 The use of thiosemicarba-
zone chelating ligands is a strategy to suppress this problem.
Furthermore, the coordination of such ligands to palladium
could give rise to compounds with a mechanism of action dis-
tinct from that of ‘cisplatin like’ complexes, since thiosemicar-
bazone derivatives complexes have shown different molecular
targets.5,18,19
In this work, new palladium complexes derived from pyrene
thiosemicarbazones were prepared, and designed to have
sufficient stability against hydrolysis in solution together with
a ‘non-cisplatin like’ mechanism of action against cancer cells,
to overcome the acquired resistance of platinum-based drugs.
In view of such potential, the compounds have been studied
against A2780 and cisplatin-resistant A2780Cis cancer cell
lines and also towards non cancer cells (MRC5). Furthermore,
the complexes, cellular accumulation and distribution, inter-
action with DNA and potential activity as TopIB inhibitors
were evaluated to explore their mechanism of action.
Results and discussion
Synthesis and characterization of the compounds
The ligands HPrR (R = ethyl and cyclohexyl) were synthesized
via condensation reactions of the corresponding thiosemicar-
bazide derivative with 1-pyrenecarboxaldehyde (more details in
ESI†). The synthesis of the complexes [PdCl(PPh3)(PrCh)] (1)
and [PdCl(PPh3)(PrEt)] (2) consisted on 1 : 1 reactions between
[PdCl2(MeCN)2] and the appropriate HPrR ligand, with final
addition of PPh3.
1H and 13C NMR results support the pro-
posed structures for all ligands and complexes prepared. The
palladium complexes were further studied by 31P NMR. The
purity of these compounds was confirmed by elemental ana-
lyses and HPLC studies. The high resolution electrospray
ionization mass spectrometry (ESI-MS) spectra showed peaks
for [M + Na]+ for the free ligands and [M − Cl]+ for the palla-
dium complexes (m/z 752.1485 for 1 and m/z 698.1019 for 2),
indicating that the Pd–Cl bond breaks under the experimental
conditions used.
The absorption and emission spectra of the free ligands
and complexes were recorded. The ligands HPrCh and HPrEt
absorb in the region 382–407 nm and around 282 nm. These
bands are most probably due to π–π* electronic transitions
associated to the polycyclic aromatic fragment of the ligands.20
The electronic spectra of complexes 1 and 2 are similar, dis-
playing strong absorptions in the 280–410 nm range. These
bands may be attributed to a combination of intraligand and
ligand-to-metal charge transfer (LMCT) transitions.21
The room temperature emission spectroscopic properties of
the thiosemicarbazone ligands were investigated using an exci-
tation wavelength of 415 nm. The emission spectra obtained for
both free ligands show two emission bands, at 429 and 448 nm,
while complexes 1 and 2 display only one broad band at
540 nm. The fluorescence intensity for both complexes 1 and 2
is clearly less than that of the respective free ligands, evidence
that the fluorescence is quenched in the metal complexes.22
X-ray crystal structure analyses were determined for the
ligands HPrCh and HPrEt (ESI, Fig. S1†) and complexes 1 and
2. Fig. 1 shows the molecular structure of complex 1, while
that of complex 2 is in Fig. S2.† The molecular structures of
both the complexes are very similar and show that the metal
center is coordinated by the thiosemicarbazone ligands in
monoanionic bidentate mode through the nitrogen and sulfur
atoms, forming a 5-membered ring. The PPh3 phosphorus
atom and the chlorido ligand occupy the remaining coordi-
nation sites, forming a distorted square-planar environment
around the palladium(II) atom. The bond distances Pd–N(1),
Pd–S(1), Pd–Cl(1) and Pd–P(1) for both complexes 1 and 2 are
comparable with those of other thiosemicarbazone derivatives
reported in literature.23–25 Upon complexation with the metal
ion, an elongation of the S(1)–C(2) bond length is observed, in
accordance with the coordination via the sulfur atom in a
thioenolate form. The N(2)–C(2) bond lengths in 1 [1.294(3) Å]
and in 2 [1.302(3) Å] are also consistent with the deprotonation
of the thiosemicarbazone ligands after coordination, as
observed for other thiosemicarbazone derivatives.26,27 Selected
bond lengths and angles are listed in Tables S1 and S2.†
The stability of complex 1 was monitored by 1H and 31P
NMR in DMSO-d6 : D2O (80% : 20%) solution for a 24-hour
period. The spectra remained unchanged during the assay
time, showing that the compound does not hydrolyze under
such conditions (Fig. S3†).
Antiproliferative activity of the compounds
Biological studies were carried out on A2780 human ovarian
carcinoma cells for both ligands and complexes. The com-
plexes were further evaluated against A2780Cis (human
ovarian carcinoma cisplatin-resistant cells). The results are
shown in Table 1. The free ligands were inactive towards the
A2780 cell line, with IC50 values >50 μM. In contrast, the com-
plexes are highly potent. Changing the R substituent group in
the thiosemicarbazone ligand affects the antiproliferative
activity of the complex, as observed for complexes 1 (cyclohexyl
derivative, IC50 = 7.59 μM) and 2 (R = ethyl, IC50 = 0.74 μM).
The experiments using cisplatin-resistant A2780Cis cell line
Fig. 1 Crystal structure of the complex 1.
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showed that the potency of complex 1 is increased when com-
pared to that observed for A2780, with an IC50 value of 3.16 ±
0.02 μM. In contrast, complex 2 loses its potency in A2780 cells
resistant to cisplatin, with the IC50 value increasing to 35.8 ±
0.8 μM. Cisplatin (CDDP) cross-resistance factors are shown in
Fig. 2A (values in Table 1). The bars are expressed as the ratio
between the IC50 values in the resistant cell line divided by the
IC50 values for the parental cell line. These results suggest that
complex 1 may have a different mechanism of action com-
pared to CDDP, since this complex overcomes CDDP resistance
and increases potency in the A2780Cis cells, with a cross-resis-
tance factor of 0.41 ± 0.01 μM. On the other hand, the resis-
tance factor for complex 2 (48 ± 0.6) is very high compared to
complex 1 and cisplatin, being less potent in A2780cis.
Additionally, we investigated activity of the complexes towards
non-cancerous cell line MRC-5 human embryonal lung fibro-
blasts (Table 1). The complexes exhibit high IC50 values for
MRC5 human fibroblasts, showing low toxicity against healthy
normal cells. Both palladium(II) complexes are nontoxic
towards the healthy cells and present relatively high activity,
affording high SF values for A2780 cells as well as for
A2780Cis. In the case of A2780, complex 2 is the most selective
(SFA2780 > 135). On the other hand, considering the selectivity
for the cisplatin resistant cell line, complex 1 presents the
higher selectivity (SFA2780Cis > 31.6). In both cell lines, the com-
plexes are more selective than cisplatin, with SF = 9.08 ± 0.3,
Table 1. Therefore, complex 1 appears to be a promising candi-
date to circumvent cisplatin resistance in ovarian cancer cells.
Cellular accumulation and distribution in A2780 cell line
The cellular accumulation of the palladium complexes, cispla-
tin and carboplatin was determined in A2780 cells, in order to
correlate with the IC50 values in this cell line. The structural
modification of changing a cyclohexyl group to an ethyl group
affected significantly the cellular uptake. The results indicate
that the accumulation for complex 1 (R = cyclohexyl) is higher
than that of complex 2 (R = ethyl), with almost 7 ng of Pd per
106 cells (Fig. 2A) inside the A2780 cell line. These data are in
accordance with the available amount of palladium for cellular
uptake for complexes 1 and 2, which are 10 ng and 1.1 ng of
palladium, respectively. Thus, 70% of complex 1 enters the
cells, while only 18% of complex 2 is able to cross the cellular
membrane. However, the results show that there is no corre-
lation between cellular accumulation and the antiproliferative
activities, since the complex 1 is the most lipophilic and pre-
sented the higher uptake but is less cytotoxic compared with
complex 2.
We also investigated cell uptake by fluorescent imaging of
A2780 cells treated with complex 1. It was possible to observe
transport of the complex was into the interior of the cells,
through a weak fluorescent green signal, when the compound
was excited at 514 nm. The cell distribution of complex 1 was
determined. Fig. 2B shows the distribution of Pd and its per-
centage in four cellular fractions, the cytoplasm, membrane,
nucleus and cytoskeletal fraction. It is notable that the highest
amount is found in the cytoskeletal. The amount of palladium
accumulated in the nuclear fraction is high (ca. 3%), compared
to the amount of platinum from cisplatin in the nuclear
portion <1%.28 Considering the amount of palladium in the
nucleus, DNA binding studies were performed, since DNA is
generally known to be the main target of cisplatin.
DNA interaction
DNA melting titration. DNA is a target of many drugs that
are currently in clinical use or in advanced clinical trials.29 In
order to understand the effect of the complexes on cancer cell
lines some DNA interaction studies were carried out. Thermal
denaturation of CT-DNA treated with the palladium complexes
was studied. Due to the low solubility of the complexes in
buffer solutions, the samples used in the measurements con-
tained 5% of DMSO. The results obtained are summarized in
Fig. 3A. The two complexes had no effect on the thermal stabi-
lity of DNA, giving rise to only a minor change (increase) in
melting temperature on incubation for 24 hours.
Table 1 IC50 values for the compounds. RF: resistance factor. SF: selectivity factor. Nd: not determined. CARB: carboplatin
A2780 (μM) A2780cis (μM) RF MRC5 (μM) SFA2780 SFA2780Cis
HPrEt >50 nd nd nd nd nd
HPrCh >50 nd nd nd nd nd
1 7.6 ± 0.3 3.16 ± 0.02 0.41 ± 0.01 >100 >13 >31.6
2 0.74 ± 0.09 35.8 ± 0.8 48 ± 6 >100 >135 >2.8
CDDP 1.20 ± 0.03 12.3 ± 04 10 ± 2 10.9 ± 0.3 9.08 ± 0.3 0.88
CARB 10 ± 1 nd nd nd nd nd
Fig. 2 (A) Cellular accumulation of palladium (ng Pd per 106 cells) (up)
uptake results and correlation of IC50 values (μM) for complexes 1 and 2
(down). (B) Distribution of Pd for complex 1 in A2780 ovarian cells.
Concentration used was IC50, pre-incubation time in drug free medium
was 24 h and drug exposure time was 24 h.
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Linear dichroism. Linear dichroism (LD) of DNA in the pres-
ence of the metal complexes was studied. LD titration of ct-
DNA with complex 1 and the resulting titration curve is shown
in Fig. 3D. No additional LD peaks were observed in the visible
part of the spectrum. In the UV range, weak signals were
observed at high compound concentrations, but these are
obscured by the strong DNA signals in those regions. The results
of the LD titrations have shown a minor increase in the LD
signal only for the two first concentrations used, 10 and 20 μM,
of complex added. From 30 μM to 100 μM a slight decrease in
the LD signal was observed, indicative of kinking or aggregation
upon binding the DNA strands.30 This phenomenon results in a
lower linearity of DNA, causing a decrease or even complete loss
of the negative signal at 260 nm, indicative of a groove binder
instead of an intercalator.31 However, the discreet changes
observed in the LD spectra compared with the spectrum in
absence of complex (0 μM, black line) are inconclusive.
DNA cleavage studies. In control experiments, where the
complex was absent (lane 1) or only DNA-DMSO (lane 2) were
incubated, no photocleavage was observed (Fig. 3C). The DNA
cleavage studies performed for the palladium complexes in
different concentrations show that at low concentrations the
complexes do not have a strong interaction with plasmid DNA.
Flow cytometry. The cell cycle histograms are shown in
Fig. 3B. Despite of the structural similarity of complexes 1 and
2, the experimental results have indicated different effects over
the cell cycle profile of A2780 cells. In the control experiment,
the G2/M and S phases represent 7.9% and 18.6%, respect-
ively, of the cell population, but upon treatment with com-
plexes 1 and 2 (cells treated using equipotent IC50 concen-
trations) the cell cycle was arrested at the G2/M stage for
complex 1 and in the S phase for complex 2. The population in
G2/M phase increases after 24 h of exposure to the complex 1
(from 7.9% to 30%), together with a slight rise of the popu-
lation in S stage as well (from 18.6% to 24%). In contrast,
complex 2 causes arrest in the S phase, with an increase from
18.6% to 38.2%. These results show that complex 2 induced
DNA damage and blocked DNA synthesis in the cells which
consequently induces S-phase arrest. It is well established that
the cytotoxicity of camptothecin is related to a collision mecha-
nism between replication forks and Top I cleavable complex.32
This collision is consistent with the generally accepted notion
that DNA damage leads to cell cycle arrest interfering with the
S phase, causing cell cycle arrest at the G2 phase of the cell
cycle. Consequently, when a damage repair is difficult or
incomplete, the cells undergo apoptosis.33 A similar inhibition
of the cell cycle at the G2/M phase has been recently observed
for comparable ruthenium thiosemicarbazone complexes.34
The details of the cell cycle assay for the palladium complexes
are shown in Table S4 (ESI†).
Topoisomerase IB assays. The DNA interaction experiments
did not clearly indicate if DNA might be a target for these com-
plexes. So, TopIB inhibition studies were performed to investi-
gate if this enzyme, that is deeply involved in DNA replication,
repair and transcription, could be a possible target. The
efficacy of the free ligands and complex 1 in the inhibition of
TopIB was tested through supercoiled plasmid relaxation
assays. Complex 1 inhibited the enzyme at a concentration of
0.75 μM with complete inhibition at 12.5 μM (Fig. 4). It is
interesting to note that the free ligands did not inhibit the
enzyme appreciably at comparable concentrations (see
Fig. S4†), which is in accordance with the lack of cytotoxicity
presented by those compounds (Table 1).
An analysis of the cleavage and religation kinetics was
carried out in order to better understand the modality of topoi-
somerase I inhibition by complex 1. The cleavage assay was
carried out using the CL14/CP25 suicide substrate, radio-
labelled at the 5′ end of the CL14. The enzyme is able to cleave
this substrate but it is not able to carry on the religation step
Fig. 3 (A) Comparison of the Tm (K) for CT-DNA when incubated with
palladium complexes 1 and 2 (B) FL2-H histograms obtained by flow
cytometry for cell cycle analysis of control untreated cells; cells treated
using 7.5 μM of complex 1; cells treated using 0.7 μM of complex 2; (C)
ethidium bromide stained agarose gel (0.5 g ml−1) of pBlue Script KSII(+)
plasmid DNA (0.25 µg µL−1) in the presence of increased concentration
of the complexes after 30 min of incubation at 37 °C: lane 1, plasmid
DNA control; lane 2, plasmid DNA + DMSO control, lane 3–10, plasmid
DNA + complexes 1 at 0.75, 1.5, 3, 6, 12.5, 25, 50, 100, 200 and 300 μM.
FI: supercoiled DNA, FII: opened circular, FIII: linear DNA; (D) linear
dichroism (LD) spectra of 100 μM DNA with increasing concentration of
complex 1. For all experiments, drug exposure time was 24 h, cells were
treated with RNAse and stained using PI.
Fig. 4 Relaxation of negative supercoiled plasmid DNA by TopIB in
presence of increasing concentrations of complex 1. Lane 1, no protein
added; lane 2, control reaction with DNA and the maximum compound
concentration (300 μM); lane 3, positive control reaction with DNA and
enzyme in absence of the compound. The reaction products were
resolved in an agarose gel and visualized with ethidium bromide. SC,
supercoiled plasmid DNA.
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because the cleaved dinucleotide is too short to be religated.35
The PAGE analysis of the reaction products, as a function of
time, is shown in Fig. S5† (upper panel), where the band
corresponding to the cleaved DNA fragment is indicated as
“cleavage”. It is interesting that the substrate is cleaved in a
fast and efficient way either in the absence or in the presence
of complex 1 at 25 μM concentration, i.e. a concentration that
produce full relaxation inhibition (Fig. 4). The complete
inability of complex 1 to inhibit the cleavage reaction is con-
firmed by plotting the percentage of the cleavage product as a
function of time in presence and absence of the compound
(Fig. S4,† lower panel).
The religation reaction was carried out by incubating, for
30 min, the oligonucleotide CL14/CP25 substrate with the TopIB
enzyme, allowing the enzyme substrate complex to produce the
cleaved complex (Fig. 5). After the cleavage has occurred, the
R11 complementary strand is added, to start the religation
process. At different times, aliquots were removed, treated with
SDS, trypsinized and analyzed by PAGE electrophoresis (Fig. 5,
upper pannel). The percentage of religation, plotted in Fig. 5
(lower panel), shows that in the presence of 25 μM complex 1
the inhibitory effect is > 60%. This result is very interesting since
it clearly shows that complex 1 acts as a poison since it is able to
inhibit the DNA religation but not the cleavage.
Conclusions
In conclusion, we have described the synthesis and character-
ization of stable new palladium(II) complexes with thiosemicar-
bazonate ligands derivatized with pyrene. The in vitro biologi-
cal data show promising low micromolar antiproliferative
activity against A2780 and also A2780cis resistance cell lines.
Complexes 1 and 2 were relatively less-toxic towards normal
cells, but complex 2, in contrast to complex 1, was cross-resist-
ant with the anticancer drug cisplatin I in ovarian cancer cell
lines. Cell cycle studies in A2780 ovarian cells showed that
complexes 1 and 2 exhibit cytotoxicity by causing G2/M and S
phase arrest. Investigations of the mechanism of action, show
that TopIB is a plausible target for complex 1. Interestingly the
compound inhibits the religation reaction without inhibiting
the DNA cleavage. TopIB can be inhibited by several com-
pounds and the inhibitors are divided into two classes
depending on the different ways they interact with the
enzyme.36–38 Poisons inhibit the enzyme at the level of the reli-
gation stabilizing the DNA-TopI cleavage complex and catalytic
inhibitors prevent the DNA binding or inhibit the cleavage
reaction.39–41 Some of them are able to inhibit both the clea-
vage and religation reaction.10,42 The poisons, such as camp-
tothecin (CPT), are the most interesting inhibitors, in fact CPT
derivatives such as topotecan and irinotecan are in clinical
use.43,44 The here studied complex 1 behaves as a poison
making it an interesting candidate to chemotherapy.
Moreover, since resistance is one of the major challenges to be
overcome in the use of chemotherapy for cancer treatment,
palladium complexes which are active against resistant
A2780cis cell lines are interesting as alternative antitumor
agents. Therefore, the complexes studied here might be con-
sidered promising lead candidates for cancer therapy.
Experimental section
General methods and materials
Chemistry. 1-Pyrenecarboxaldehyde, 4-etyl-thiosemicarba-
zide, analytical reagents grade chemicals and solvents were
purchased from Sigma-Aldrich and used without further
purification. The 4-cyclohexyl-3-thiosemicarbazide and
[PdCl2(MeCN)2] were prepared as described previously.
45,46
Fourier transform infrared spectroscopy. FTIR spectra between
400 and 4000 cm−1 were measured via the Potassium Bromide
(KBr) pellet method using a Shimadzu IR Prestige-21 spectro-
photometer. 1H, 31P and 13C NMR spectra were acquired in
5 mm NMR tubes at 298 K on a Bruker DPX 400 (1H =
400.13 MHz, 31P = 161.98 MHz, 13C at 100.61 MHz) spectro-
meter. 1H NMR chemical shifts were internally referenced to
CD2Cl2 (5.32 ppm) for dichloromethane or DMSO (2.50 ppm)
for dimethyl sulfoxide-d6. All data processing was carried out
using ACDLabs software. Electrospray ionization mass spectra
were obtained by preparing the samples in 10% acetone and
90% MeOH (v/v). The mass spectra were recorded with a scan
range of m/z 400–1000 for positive ions. CHN elemental ana-
lyses were carried out on a CE-440 elemental analyzer by
Warwick Analytical (UK) Ltd or a PerkinElmer CHNS/O 2400
Series II equipment. LC-MS data were recorded on a Bruker
Amazon X instrument coupled with an Agilent Technologies
Fig. 5 Upper panel: Gel analysis of the religation kinetics with the
CL14/CP25 substrate for TopIB in DMSO (lanes 2–9) and in presence of
25 μM of complex 1 (lanes 10–18). Lower panel: The graphic shows the
percentage of the religation product plotted at different times for topoi-
somerase IB. The data reported are the average ± SD of three indepen-
dent experiments.
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1200 series HPLC instrument was used. The HPLC column
was an Agilent ZORBAX Eclipse Plus C18 250 × 4.6 mm
column with a pore size of 5 µm. Mobile phases consisted of
doubly deionized water 0.1% TFA and HPLC grade acetonitrile
0.1% TFA. Unfiltered volumes of <200 μL were injected and
analyzed at a detection wavelength of 254 nm. HPLC chroma-
tograms were analyzed and integrated using DataAnalysis soft-
ware. Sample injection volumes were 20 μL and the mass
spectrometer was operated in electrospray positive mode with
a scan range of 50–2000 m/z. The following solvent gradient
and 1 mL min−1 flow rate was used: time (min)/% (B): 0 (min)/
10%, 30 (min)/80%, 40 (min)/80%, 41 (min)/10%, 55 (min)/
10%. For the biological assays as CT-DNA melting and linear
dichroism (LD) titrations, CT-DNA was also obtained from
Sigma Aldrich. The HPLC analysis of complexes was carried
out on an Agilent Technologies 1200 series HPLC instrument
with a VWD and 100 μL loop, and an Agilent ZORBAX Eclipse
Plus C18 250 × 4.6 mm column with a pore size of 5 μm was
used. The mobile phases used were (A) H2O and (B) MeCN
both containing 0.1% of TFA (HPLC grade materials were
used), following the solvent gradient flow described above.
Samples were prepared at 100 μM concentration in 100% of
MeCN of complexes 1 and 2 using HPLC grade solvents and fil-
tered through Iso-DiscTM filters (PTFE-4-4 4 mm × 0.45 μm).
Sample volumes of 50 μL were injected and analyzed at a
detection wavelength of 254 nm. The chromatograms were
analysed using ChemStation software. UV-Vis spectra of solu-
tions diluted in dichloromethane/DMSO were recorded using a
Shimadzu UV-1800 spectrophotometer.
Orange crystals were produced via slow evaporation of the
mother solution of complex 1 and mixture of solvents
CH2Cl2 : MeOH (1 : 1) of complex 2 at room temperature. Data
collection was performed at 296 K by applying Mo-Kα radiation
(λ = 71.073 pm) using a Bruker Kappa APEX II Duo diffract-
ometer (Bruker®, Karlsruhe, Germany). The multi-scan
method was applied for absorption correction. The structures
were solved with SHELXS97 47 software using direct methods,
and all non-hydrogen atoms were refined with anisotropic dis-
placement parameters in SHELXL97.48 The hydrogen atoms
were calculated at idealized positions using the riding model
option of SHELXL2014.48 Table S3† presents more detailed
information about the structure determinations. The structural
data have been deposited in The Cambridge Crystallographic
Data Centre with accession numbers of CCDC
1866632–1866635† for compounds HPrCh, HPrEt, 1 and 2,
respectively.
Inductively Coupled Plasma-Optical Emission Spectrometry
(ICP-OES) analyses were carried out on a PerkinElmer Optima
5300 DV series ICP-OES. The water (18.2 MΩ) used for analysis
was doubly deionized (DDW) using a Millipore Milli-Q water
purification system and a USF Elga UHQ water deionizer. ICP
standards for platinum (1001 ± 2 μg ml−1, Fluka) and palla-
dium (1015 μg mL−1, Aldrich) were diluted with 3.6% HNO3
DDW to freshly prepare calibrants at concentrations of 50–700
ppb, which were spiked with NaCl to match the salt content of
the samples being analyzed. All Inductively Coupled Plasma-
Mass Spectrometry (ICP-MS) analyses were carried out on an
Agilent Technologies 7500 series ICP-MS instrument. ICP stan-
dards were diluted with 3.6% HNO3 DDW to prepare freshly
calibrants at concentrations of 0.1–1000 ppb. The ICP-MS
instrument was set to detect Pd and Pt with typical detection
limits of ca. 2 ppt using no-gas mode, with an internal cali-
bration standard of Er (50 pp).
Preparation of the complexes. A solution of HPrR
(0.1 mmol) with [PdCl2(MeCN)2] (0.1 mmol) in MeCN was
stirred at ambient temperature for 24 h. After this time, one
mol equiv. PPh3 (26.2 mg, 0.1 mmol) in MeCN was added. The
reaction mixture was stirred at ambient temperature for 24 h.
Orange crystals formed for mother solution of 1 were collected
by filtration after two days and crystals of 2 were obtained by
recrystallization in mixture of DCM :MeOH (1 : 1).
Data for [PdCl(PPh3)(PrCh)] (1) (788.6 g mol
−1). Color:
orange. Yield: 40 mg (76%). M.P.: decomposes 278–280 °C. IR
(νmax/cm
−1): 3394 ν(N–H), 1583, 1527 ν(CvN) + ν(CvC), 1095
ν(P–C), 746 ν(CvS). 1H NMR (CD2Cl2): δ 1.05–1.28 (m, 6H, C̲h ̲–
H), 1.65–1.69 (m, 2H, Ch–H), 2.00–2.03 (m, 2H, Ch–H),
3.48–3.55 (m, 1H, C̲H ̲–Ch), 4.64 (s, 1H, N̲H ̲–Ch), 7.44–7.53 (m,
9H, PPh3–H), 7.80–7.5 (m, 6H, PPh3–H), 7.99–8.22 (m, 6H, Pr–
H), 8.62 (d, 1H, 3J = 8 Hz, Pr–H), 9.15 (d, 3J = 8 Hz, 1H, Pr–H),
9.77 (d, 3J = 4 Hz, 1H, Pr–H). 31P NMR (CDCl3): δ 27.53.
13C
NMR (APT, CD2Cl2): δ 24.92 (CH2), 25.63 (CH2), 32.89 (CH2),
55.75 (CH), 123.16 (CH), 123.91 (CH), 124.42 (C), 124.51 (C),
125.27 (C), 126.01 (CH), 126.05 (CH), 126.20 (CH), 127.26 (CH),
128.20 (CH), 128.34 (CH), 128.77 (CH), 128.94 (CH), 129.14
(CH), 129.91 (C), 130.56 (C), 130.63 (C), 131.11 (C), 131.13
(CH), 131.17 (CH), 131.24 (C), 132.73 (C), 134.54 (CH), 134.69
(CH), 150.51 (CH). Anal. Calcd for C42H38ClN3PPdS·H2O: C,
62.53; H, 4.87; N, 5.21%. Found: C, 62.23; H, 4.69; N, 5.11%.
IV (νmax/cm
−1): 3394 ν(N–H), 1583, 1517 ν(CvN) + ν(CvC),
1095 ν(P–C), 746 ν(C–S). UV–Vis, CH2Cl2 solution concen-
tration: 9.8 × 10−5 M [λmax (ε, L mol
−1 cm−1)]: 400.50 nm
(41 430), 284.00 nm (32 448). MS (ESI+): m/z for
C42H38ClN3PPdS [M − Cl]+: calcd 752.1490, found 752.1485.
HPLC: Rt = 40.5 min (at 254 nm).
Data for [PdCl(PPh3)(PrEt)] (2) (734.59 g mol
−1). Color:
orange. Yield: 38 mg (52%). M.P.: 215–217 °C. IR (νmax/cm
−1):
3356 ν(N–H), 1584, 1527 ν(CvN) + ν(CvC), 1091 ν(P–C), 756
ν(CvS). 1H RMN (CD2Cl2): δ 1.13 (t,
3J = 6.0 Hz, 3H, –CH2C̲H ̲3),
3.31 (dq, 3J1 = 6.0 Hz,
3J2 = 3 Hz, 2H, –NHC̲H ̲2CH3), 4.82 (s, 1H,
N ̲H ̲ –Et), 7.47–7.57 (m, 9H, PPh3–H), 7.78–7.84 (m, 6H, PPh3–
H), 8.03–8.27 (m, 8H, Pr–H), 8.56 (d, 3J = 9 Hz, 1H, Pr–H), 9.18
(d, 3J = 9 Hz, 1H, Pr–H), 9.72 (d, 1H, 3J = 6 Hz, 1H, Pr–H). 31P
NMR (CD2Cl2): δ 27.56.
13C NMR (APT, CD2Cl2): δ 14.45 (CH3),
41.41 (CH2), 123.17 (CH), 124.02 (CH), 124.41 (C), 125.34 (C),
126.02 (CH), 126.05 (CH), 126.20 (CH), 127.26 (CH), 128.20
(CH), 128.35 (CH), 128.75 (CH), 128.95 (CH), 129.11 (CH),
129.88 (C), 130.56 (C), 130.61 (C), 131.11 (C), 131.15 (CH),
131.18 (CH), 132.72 (C), 134.54 (CH), 134.68 (CH), 150.94 (CH).
Anal. Calcd for C38H31ClN3PPdS: C, 62.13; H, 4.25; N, 5.72%.
Found: C, 61.51; H, 4.18; N, 5.64%. UV–Vis, CH2Cl2 solution
concentration: 5.1 × 10−5 M [λmax (ε, L mol
−1 cm−1)]:
408.00 nm (15 128), 393.50 nm (15 326), 286.50 (13 702). MS
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(ESI+): m/z for C38H31ClN3PPdS [M − Cl]+: calcd 698.1019,
found 698.1019. HPLC: Rt = 38.4 min (at 254 nm).
Cell culture. A2780 and A2780Cis human ovarian carcinoma
cells were obtained from the European Collection of Cell
Cultures (ECACC) and used between passages 5 and 18.
MRC-5 human fetal lung fibroblasts were also obtained from
the same source. All cell lines were grown in Roswell Park
Memorial Institute medium (RPMI-1640) supplemented with
10% v/v of fetal calf serum, 1% v/v of 2 mM glutamine and 1%
v/v penicillin/streptomycin. They were grown as adherent
monolayers at 310 K in a 5% CO2 humidified atmosphere and
passaged at approximately 70–80% confluence.
In vitro growth inhibition assay. Briefly, 5000 cells were
seeded per well in 96-well plates. The cells were pre-incubated
in drug-free media at 310 K for 48 h before adding different
concentrations of test compounds. Stock solutions of the PdII
complexes were firstly prepared in 5% DMSO (v/v) and a mixture
0.9% saline and RPMI-1640 medium (1 : 1) (v/v) following serial
dilutions in RPMI-1640. The drug exposure period was 24 h.
After this, supernatants were removed by suction and each well
was washed with PBS. The cells were allowed to recover for a
further 72 h in drug-free medium at 310 K. The SRB assay was
used to determine cell viability.49 Absorbance measurements of
the solubilized dye (on a BioRad iMark microplate reader using
a 470 nm filter) allowed the determination of viable treated cells
compared to untreated controls. IC50 values were determined as
duplicates of triplicates in two independent sets of experiments
and their standard deviations were calculated.
Metal accumulation in cancer cells
Cell seeding. Briefly, 4 × 106 cells were seeded in a P100
Petri dish using 10 ml of culture medium and incubated at
310 K for 24 h.
Sample preparation. 100 μM solution of each compound to
be tested were prepared in cell culture medium containing 5%
v/v DMSO. Exact concentration of palladium was determined
by ICP-OES (using freshly prepared calibration standards,
50–700 ppb, with standard addition of sodium chloride to
match the sample matrix). The stock solutions were diluted
with culture medium to achieve final working concentration
equal to IC50.
Drug addition. The supernatant medium was removed, and
10 mL of each compound to be tested was added to triplicate
the Petri dishes. Cells were exposed to the drugs for 24 h.
Drug removal. Supernatants were removed by suction. Cells
were washed with PBS and detached using trypsin/EDTA and a
single cell suspension was obtained using culture medium.
Cells were counted using a hemocytometer, and centrifuged
(1000 rpm, 5 min, 277 K) to obtain whole-cell pellets.
Sample digestion. Cell pellets were digested in 72% v/v
nitric acid using a CEM Discovery SP microwave reactor
(3 min, 393 K, 150 W, 250 psi) then diluted to working acid
concentration of 3.6% v/v. Samples were analyzed using an
Agilent 7500 series ICP-MS in both no-gas and He-gas mode.
Calibration samples for Pd (0.1–1000 ppb) were freshly pre-
pared in 3.6% v/v nitric acid. Total dissolved solids for ICP-MS
analysis did not exceed 0.1% w/v. Final metal accumulation
was reported as ng Pd × 106 cells and standard deviations were
calculated.
Cellular metal distribution. Experiments were conducted
similarly to the metal accumulation protocol described above,
following identical cell seeding, sample preparation, and drug
addition. Modifications during drug removal included the use
of the fractionPREP kit from Biovision, according to manufac-
turer’s instructions once the whole-cell pellets had been
obtained. Sample digestion and ICP-MS metal quantification
were conducted as above.
CT-DNA melting. The stability of DNA in the presence of the
metal complexes was recorded by measuring the absorbance at
260 nm while increasing the temperature between 323 and
368 K. The DNA concentration was determined by UV absor-
bance at 260 nm based on DNA base pairs π–π* transitions48
and the known extinction coefficient at this wavelength (6600
L mol−1 cm−1).50 The melting curves of untreated and treated
CT-DNA were recorded using a fixed ratio of 1 : 1 Pd
(II) : CT-DNA (45 μM of both complex and CT-DNA). The value
of the melting temperature (Tm) as the temperature when 50%
of the present double-stranded CT-DNA converts into single-
stranded CT-DNA was determined as the corresponding
maximum on the first-derivative profile of the melting curves.
Complexes were incubated for 24 hours with 5% DMSO.
Linear dichroism (LD) titrations. All solutions were prepared
in 1 mM Tris (pH 7.6), 5% DMSO buffer. The CT-DNA concen-
tration was kept constant throughout the experiment at
100 μM, and the complex 1 concentration was increased from
0 to 100 μM. DMSO concentration was kept constant at 5%.
Complex 1 were incubated for 24 hours with DNA before the
LD measurement. The LD scans were run from 200 nm to
450 nm with 3 accumulations.
stabi analysis by flow cytometry. All flow cytometry experi-
ments were carried out using a Becton Dickinson FACScan
Flow Cytometer in the School of Life Sciences at Warwick
University. Typically, A2780 cells were seeded in Petri dishes
using 4 × 106 cells per plate. Experiments included 24 h of
pre-incubation in drug-free media at 310 K in CO2 humidified
atmosphere, followed by 24 h of drug exposure under the same
conditions. After this, samples were collected after trypsiniza-
tion, washed with PBS and stained in the dark with a mixture
of propidium iodide and RNAse. After 30 min staining, cell
samples were washed and set up for flow cytometry reading on
the red channel FL-2.
DNA cleavage studies using agarose gel electrophoresis. In
the gel electrophoresis experiments, supercoiled pBlue-Script
KSII(+) DNA was incubated with increasing metal complexes
concentrations for 30 min at 37 °C. 7.5 µL of SDS 4× STOP dye
were added (25% Ficol 400, 2.5% SDS, 25 mM EDTA, 0.03%
blue of bromofenol, 0.03% xilenocianol)and the samples were
analyzed by 1% agarose gel electrophoresis, run for 18 h at
30 V in TBE buffer (Tris 50 mM, boric acid 45 mM and 1 mM
of EDTA). The gel was stained with 0.5 μg mL−1 ethidium
bromide, washed with distilled water, visualized by UV light,
and photographed for analysis.
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Purification of human topoisomerase IB. Multicopy plas-
mids, YCpGAL1-e-hTopIBwt and YCpGAL1-e-hTopIBY723F
were used for transformation of Saccharomyces cerevisiae TopI
null strain EKY3 (ura3-52, his3_200, leu2Δ1, trp1Δ63, top1:
TRP1, MATα), as previously described.32 The plasmids have a
galactose-inducible promoter and the constructs contain at the
N-terminal the sequence FLAG (DYKDDDY), indicated with
“e”. This sequence is recognized by the M2 monoclonal anti-
body and its purification was carried out using the ANTI-FLAG
M2 Affinity Gel (Sigma-Aldrich) column. The transformed cells
grew overnight on synthetic complement (SC)-uracil plus 2%
dextrose. After dilution 1 : 100 in SC-uracil plus 2% raffinose,
cells were induced with 2% galactose for 6 h. After enzyme
extraction, the extracts were loaded into ANTI-FLAG M2
Affinity Gel (Sigma-Aldrich) column, already equilibrated
according to manufactures’ instructions. The FLAG-fusion
topoisomerase IB was eluted by competition with five column
volumes of a solution containing 200 μg ml−1 FLAG peptide in
50 mM Tris-HCl, 150 mM KCl pH 7.4. Glycerol was added into
each collected fraction up to a final concentration of 40%. All
the fractions were stored at −20 °C.
DNA relaxation assays. The enzyme activity was assayed at
37 °C, in 30 μl of reaction volume containing 0.5 μg of nega-
tively supercoiled pBlue-ScriptKSII(+) as a substrate in reaction
buffer (20 mM Tris-HCl, 0.1 mM EDTA, 10 mM MgCl2, 50 μg
ml−1 acetylated BSA and 150 mM KCl, pH 7.5). Reactions were
stopped with 0.5% SDS after each time point. The effect of the
compound on enzyme activity was measured by adding the
indicated concentration of the compound to the reaction tube.
DMSO was used as positive control, in a final concentration of
3.3%. The samples were electrophoresed in 1% agarose gel in
TBE buffer (50 mM Tris, 45 mM boric acid, 1 mM EDTA). The
gels were stained with ethidium bromide (0.5 μg ml−1),
destained with water and photographed under UV
illumination.
Kinetics of cleavage. The oligonucleotide substrate CL14 (5′-
GAAAAAAGACTTAG-3′) was radiolabeled with [γ-32P] ATP at its
5′ end. The CP25 complementary strand (5′-TAAAAATTTTTC-
TAAGTCTTTTTTC-3′) was phosphorylated at its 5′ end with
unlabeled ATP. The two strands were annealed at a twofold
molar excess of CP25 over CL14, to permit a full formation of a
partial duplex, that contains the enzyme preferred cleavage
site, as already described.51 The cleavage reactions were
carried out incubating TopIB enzyme with 20 nM of partial
duplex substrate in the presence of 25 μM complex 1 at 37 °C.
At different time points, 5 μL of reaction solution were
removed and the reactions were stopped with 0.5% SDS.
DMSO was used as positive control. After ethanol precipitation,
samples were resuspended in 6 μL of 1 mg mL−1 of trypsin
and incubated at 37 °C, for 1 h. Samples were analyzed using
denaturing 7 M urea/20% polyacrylamide gel electrophoresis
in TBE buffer. The percentage of cleaved substrate was deter-
mined by PhosphorImager and ImageQuant software compar-
ing the intensity of the CL1 product, normalized to the total
amount of radioactivity in each lane, with the maximal value
obtained at the longest time for the enzyme in the absence of
the compounds. The experiments were performed at least
three times and a representative gel is shown.
Kinetics of religation. For kinetics of religation, we used the
oligonucleotide CL14/CP25 (20 nM), prepared as explained pre-
viously. The substrate was incubated with TopIB enzyme for
30 min at 37 °C, in reaction buffer, allowing the enzyme to
perform the cleavage. After the formation of the cleavage
complex, 5 μL sample of the reaction mixture were removed
and used as the zero-time point. Religation reactions were
initiated by adding a 200-foldmolar excess of R11 oligo-
nucleotide (5′-AGAAAAATTTT-3′) over the duplex CL14/CP25, in
the presence or in the absence of compound. This allows the
enzyme to perform the religation step, restoring a full duplex
oligonucleotide, as the final product. DMSO was used as posi-
tive control. At time-course points, 5 μl aliquots were removed
and the reaction stopped with 0.5% SDS. After ethanol precipi-
tation samples were resuspended in 6 μL of 1 mg mL−1 trypsin
and incubated at 37 °C for 1 h. Samples were analyzed by
denaturing 7 M urea/20% polyacrylamide gel electrophoresis
in TBE buffer. The result was visualized by Phosphor Imager
and quantified by ImageQuant software. The experiment was
performed three times and a representative gel is shown.
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